Go to Page # Page of 10

Targeting the Endothelin A Receptor to Inhibit Cyclooxygenase Expression in Ovarian Carcinoma Cells

 Francesca Spinella,1 Laura Rosano`, Valeriana Di Castro, Maria Rita Nicotra, Pier Giorgio Natali, an
Description: New therapies against cancer are based on targeting cyclooxygenase (COX)-2. Activation of the endothelin A receptor (ETAR) by endothelin (ET)-1 is biologically relevant in several malignancies, including ovarian carcinoma. In this tumor, the ET-1/ETAR autocrine pathway promotes mitogenesis, apoptosis protection, invasion, and neoangiogenesis.
Views: 1876
Domain: Medical
Category: Biotech/Pharma
4670 Vol. 10, 4670 � 4679, July 15, 2004

Clinical Cancer Research

Featured Article

Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells
Francesca Spinella,1 Laura Rosano,1 ` Valeriana Di Castro,1 Maria Rita Nicotra,3 Pier Giorgio Natali,2 and Anna Bagnato1
Laboratories of 1Molecular Pathology and Ultrastructure and ... See more

Recent Presentations

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019

Investment Trends in Healthcare

Macroeconomic drivers are leading to an unprecedented healthcare industry change. Healthcare is one of the most impacted industry by technology breakthrough.

Danilo Mazzara
16 April, 2019